top of page
coverpage1.png

Highlights 

201005103230-02-nobel-prize-1005-large-1

HCV research with Dr. Charles Rice, 2020 Nobel Prize recipient.
(2004-2007)

Our (2004-2007) HCV research with Dr. Charles Rice, 2020 Nobel Prize recipient contributed to the following translational research which deepened knowledge of the HCV-host dynamic on the molecular level and during acute infection in chimpanzees.

  • Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees (2004) 

  • Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production (2005) 

  • Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. (2007)

Screen Shot 2024-10-10 at 1.43.52 AM.png

Large Scale RGT Clinical Trial Preview
October 2020

Success in real-time patient therapy to be tested in larger HCV treatment clinical trial with Israeli research partners. Significant implications for healthcare cost, duration of treatment and patient-care. Harel Dahari's recent work was acknowledge at a conference in South Korea.

 

Publication; Press Release; Conference

jid_small_edited.png

Ultrashort HCV Time-to-Cure Results
May 2020

Proof-of-concept HCV study yields promising results for a 4-week ultra-short, response-guided therapy treatment. Retrospective modeling of viral kinetics underscores the potential usefulness of a personalized modeling-based RGT approach to shorten the duration of treatment.

 

Publication

Capture_JPG_edited.png

Promising Results for Transplant Recipients
May 2020

Therapy combination prevents HCV infection in organ transplant recipient. Anti-viral treatment optimization results in milestone achievement in collaboration with Canadian cohort. For the patient, this results in cheaper, safer treatments, and removes the added risk of HCV while in post-transplant recovery [AASLD]. This comes at a time when HCV infection and mortality rates in younger populations are on the rise due to the ongoing opioid crisis [CDC].

 

Publication; Press Release; Comment

Sci-Reports-Nature_edited_edited.png

HBV/HDV Research Advancement
May 2020

Mathematical modeling leads to new insights in HBV/HDV research with biopharma firm Replicor. Defining Mode of Action helped unlock promising new therapy in development for HBV treatment as well as in patients coinfected with HDV.

 

Publication; Replicor Press Release

Screen Shot 2024-10-10 at 1.43.52 AM.png

Principles of Cell Circuits for Tissue Repair and Fibrosis
February 2021

DahariLab hosted Miri Adler, PhD from The Broad Institute of MIT and Harvard to discuss her research on the social behavior of cells during tissue repair and fibrosis. As part of her research, Dr. Adler developed a mathematical model to better understand the principles of this dynamic. 

ReplyForward

Add reaction

bottom of page